PCNEU04 Stock Latest News
Private CompaniesPrecision Neurology Focus Underscores Neuron23’s Parkinson’s Research Strategy1w agoNEU04
Private CompaniesNeuron23 Advances NEULARK Phase 2 Trial in LRRK2-Driven Parkinson’s Disease2w agoNEU04- Private CompaniesNeuron23 Highlights Precision Medicine Approach in Parkinson’s Clinical Trial3w agoNEU04
Private CompaniesNeuron23 Highlights Clinical Engagement Around LRRK2-Targeted Parkinson’s Program2M agoNEU04- Private CompaniesNeuron23 Highlights Engagement With Global LRRK2 Research Community3M agoNEU04
Private CompaniesNeuron23 Leadership Engages in Global LRRK2 Parkinson’s Research Forum3M agoNEU04Private CompaniesNeuron23 Emphasizes Medical Science Liaison Support for NEULARK Parkinson’s Trial4M agoNEU04
- Private CompaniesNeuron23 – Weekly Recap5M agoNEU04
Private CompaniesNeuron23 Advances Genetics-Driven Strategy in Global LRRK2 Parkinson’s Program5M agoNEU04
Private CompaniesNeuron23 Collaborates on Genetics-Focused Parkinson’s Trial Navigator Pilot5M agoNEU04
Private CompaniesNeuron23 – Weekly Recap5M agoNEU04Private CompaniesNeuron23 Highlights Global NEULARK Trial Footprint in Parkinson’s Disease5M agoNEU04
Private CompaniesNeuron23 Emphasizes Patient-Centric Global Trial Effort in Parkinson’s Program5M agoNEU04
- Private CompaniesNeuron23 Deepens Precision-Medicine Focus and Community Ties in Parkinson’s Disease6M agoNEU04
Private CompaniesNeuron23 Emphasizes Genetics-Focused Precision Strategy in Parkinson’s Research6M agoNEU04
Private CompaniesNeuron23 Emphasizes Precision-Medicine Approach in Parkinson’s Research6M agoNEU04
Private CompaniesNeuron23 Highlights Community Engagement in Parkinson’s Disease Focus6M agoNEU04
Private CompaniesNeuron23 Highlights Engagement With Parkinson’s Community and Research Ecosystem6M agoNEU04